Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimumab + nab-paclitaxel + gemcitabine for advanced pancreatic cancer (first-line, single-arm)
ChiCTR2300077985Phase 2Not yet recruiting
- Sponsor
- Kunshan Traditional Chinese Medicine Hospital
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in pancreatic cancer (PC), sponsored by Kunshan Traditional Chinese Medicine Hospital. Primary endpoint: Progression free survival. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300077985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077985.